Stoke Therapeutics Inc（STOK）の財務STOKStoke Therapeutics Inc

Evaluating the bottom line, Stoke Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -701.65%, while the net margin is -660.78%. These profitability ratios, combined with a Return on Equity (ROE) of -61.10%, provide a clear picture of how effectively STOK converts its operational activities into shareholder value.

In the context of the broader market, STOK competes directly with industry leaders such as NUVB and COAG. With a market capitalization of $1.72B, it holds a leading position in the sector. When comparing efficiency, STOK's gross margin of 100.00% stands against NUVB's 70.11% and COAG's N/A. Such benchmarking helps identify whether Stoke Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Stoke's revenue for Q2 2026 was $9.33 million, a 32.4% decline year-over-year, and it reported a GAAP EPS of -$0.93, missing expectations by $0.15. The gross margin remains high at 100%, but net income has been negative, indicating financial instability.